Health Law & Business News

Cancer Risk Forces Recall of Weight-Loss Drug Belviq (Correct)

Feb. 14, 2020, 2:29 PM

Weight-loss drug Belviq will be withdrawn from the U.S. market at the request of the Food and Drug Administration, after research tied it to increased rates of cancer.

Belviq came on the market in the U.S. in 2012 and is sold by Japanese drugmaker Eisai Co. U.S. sales of the drug peaked in 2015, with more than 600,000 prescriptions filled that year in the U.S., according to data compiled by Bloomberg and Symphony Health. Eisai’s revenue from the drug in the Americas in fiscal 2014 was $49.4 million, according to data compiled by Bloomberg.

The pill is thought to trigger...

To read the full article log in. To learn more about a subscription click here.